A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers




TekijätForsberg Lars, Spelman Tim, Klyve Pernilla, Manouchehrinia Ali, Ramanujam Ryan, Mouresan Elena, Drahota Jiri, Horakova Dana, Joensen Hanna, Pontieri Luigi, Magyari Melinda, Ellenberger David, Stahmann Alexander, Rodgers Jeff, Witts James, Middleton Rod, Nicholas Richard, Bezlyak Vladimir, Adlard Nicholas, Hach Thomas, Lines Carol, Vukusic Sandra, Soilu-Hänninen Merja, van der Walt Anneke, Butzkueven Helmut, Iaffaldano Pietro, Trojano Maria, Glaser Anna, Hillert Jan

KustantajaSAGE PUBLICATIONS INC

Julkaisuvuosi2023

JournalMultiple Sclerosis Journal - Experimental, Translational and Clinical

Tietokannassa oleva lehden nimiMULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL

Lehden akronyymiMULT SCLER J-EXP TRA

Artikkelin numero 20552173231153557

Vuosikerta9

Numero1

Sivujen määrä10

DOIhttps://doi.org/10.1177/20552173231153557

Verkko-osoitehttps://doi.org/10.1177/20552173231153557

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/179307089


Tiivistelmä

Background: To assign a course of secondary progressive multiple sclerosis (MS) (SPMS) may be difficult and the proportion of persons with SPMS varies between reports. An objective method for disease course classification may give a better estimation of the relative proportions of relapsing-remitting MS (RRMS) and SPMS and may identify situations where SPMS is under reported.

Materials and methods: Data were obtained for 61,900 MS patients from MS registries in the Czech Republic, Denmark, Germany, Sweden, and the United Kingdom (UK), including date of birth, sex, SP conversion year, visits with an Expanded Disability Status Scale (EDSS) score, MS onset and diagnosis date, relapses, and disease-modifying treatment (DMT) use. We included RRMS or SPMS patients with at least one visit between January 2017 and December 2019 if ≥ 18 years of age. We applied three objective methods: A set of SPMS clinical trial inclusion criteria ("EXPAND criteria") modified for a real-world evidence setting, a modified version of the MSBase algorithm, and a decision tree-based algorithm recently published.

Results: The clinically assigned proportion of SPMS varied from 8.7% (Czechia) to 34.3% (UK). Objective classifiers estimated the proportion of SPMS from 15.1% (Germany by the EXPAND criteria) to 58.0% (UK by the decision tree method). Due to different requirements of number of EDSS scores, classifiers varied in the proportion they were able to classify; from 18% (UK by the MSBase algorithm) to 100% (the decision tree algorithm for all registries). Objectively classified SPMS patients were older, converted to SPMS later, had higher EDSS at index date and higher EDSS at conversion. More objectively classified SPMS were on DMTs compared to the clinically assigned.

Conclusion: SPMS appears to be systematically underdiagnosed in MS registries. Reclassified patients were more commonly on DMTs.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 20:21